Duell publishes its Q4 (6-8/24) figures on Wednesday 9th of October.
Redeye comments briefly on the appointment of Philippe Cohen as new CEO while we leave our estimates...
Redeye updates its estimates for the Q3 2024 report (due 2024-10-25).
Redeye expects Smart Eye's Q3, due 14 November, to show a 21% y/y sales growth, EBITDA of SEK -19m, ...
Q3e: revenues of DKK 311m, EBIT of DKK 12m, 4% margin Small negative operational estimate revisions ...
Redeye gives a short comment on today’s news that IRLAB has enrolledthe last patient in the ongoing ...
100 patients enrolled Reduction of falls in overall study population Topline data at the end of Q1'2...
Redeye initiates coverage of MindArk, a Swedish gaming company with a long-standing presence in the ...
Redeye comments on the announcement of sales of the Nevisense device to NIH as a research tool on th...
Redeye comments on Xbrane following today's news that the FDA, like the EMA, has recieved positive f...
The company's third largest shareholder, Rasmussengruppen, have divested its entire holding in Nekka...
Redeye comments on the news that Ngenic and Svea Solar entered a strategic partnership agreement wor...
Redeye comments on the steps in the US to expand the footprint.
Nettoomsättningen uppgick till 49,2 MSEK (48,7) i det första kvartalet (maj-juli) i Purefuns brutna ...
Q3e: sales +17% EBITDA + 39% y-o-y Positive news flow incl.
Redeye embraces the positive results from the SOLARIO trial, and we argue that the company has ticke...
Redeye comments on Iconovo’s announced rights issue of units.
CFO Rasmus Untidt appointed CEO with immediate effect Following past years' restructuring and stream...
Ahead of Fiskars' Q3 report, due on 24 October, we trim our 2024E-26E top line by 1-2% and adjusted ...
Redeye comments on last night's selling from two of Truecaller's largest shareholders (Kleiner Perki...
